C.I

Chinese Canadian Museum Takes Highlights of Feature Exhibition “The Paper Trail to the 1923 Chinese Exclusion Act” on the Road

Retrieved on: 
Thursday, April 18, 2024
Chinese Exclusion Act, Courage, Canadian Museum of History, CCM, City, Toronto Reference Library, Fear, Chinese Canadians, Pier, Exhibition, Perseverance, C.I, History, Museum, Paper Trail, Room, Eye, Catherine Clément, Community, Government, Gatineau, Tourism

VANCOUVER, British Columbia, April 18, 2024 (GLOBE NEWSWIRE) -- The Chinese Canadian Museum (CCM) is pleased to announce they will be taking highlights of their feature exhibition The Paper Trail to the 1923 Chinese Exclusion Act on the road across Canada this May in recognition of Asian Heritage Month. A special video tour of the national exhibition located in the museum’s historic Wing Sang Building has been produced especially for this East Coast tour.

Key Points: 
  • Photo: Curator Catherine Clement presenting the Chinese Canadian Museum’s feature exhibition “The Paper Trail to the 1923 Chinese Exclusion Act” during the museum’s grand opening on July 1, 2023.
  • VANCOUVER, British Columbia, April 18, 2024 (GLOBE NEWSWIRE) -- The Chinese Canadian Museum (CCM) is pleased to announce they will be taking highlights of their feature exhibition The Paper Trail to the 1923 Chinese Exclusion Act on the road across Canada this May in recognition of Asian Heritage Month.
  • As Canada’s first Chinese Canadian Museum, the museum provides a meaningful and transformative experience for all, connecting Canadians to the diverse and eclectic stories and contributions of generations of Chinese Canadians, past and present — with an eye to the future.
  • Catherine Clement is an award-winning community curator whose work focuses on uncovering and sharing the lesser-known stories of the Chinese Canadian community.

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

Retrieved on: 
Thursday, August 18, 2022
Health, Infectious Diseases, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Janssen Pharmaceuticals, Liver, III, Multimedia, Johnson & Johnson, Cystic Fibrosis Foundation, CEO, Diagnosis, Messenger RNA, Private Securities Litigation Reform Act, ARCT, SEC, Clinical trial, Glycogen storage disease type III, Infection, MNT, Patent, Annual report, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Gene editing, DNA, Therapy, COVID-19, Twitter, Cystic fibrosis, Vaccine, OTC, RNA, C.I, Safety, Risk, Intention, Vaccination, Arcturus Therapeutics, MicroRNA, Hepatitis B virus, Nasdaq, Severe acute respiratory syndrome coronavirus 2, LinkedIn, RNA transfection, Omicron, Arcturus

In Figure B, three additional participants with suspected asymptomatic seroconversion were removed from the day 181 analysis (n=6, day 181).

Key Points: 
  • In Figure B, three additional participants with suspected asymptomatic seroconversion were removed from the day 181 analysis (n=6, day 181).
  • Neutralizing antibody responses against Omicron variants BA.1, BA.2, and BA.5 were measured at the Moore Lab in South Africa.
  • These data show sustained neutralizing responses to antigenically distinct variants of concern, including Omicron BA.5, for at least six months after vaccination.
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.